- Home
- STRO vs ACRV Comparison
STRO vs ACRV Comparison
Compare STRO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- ACRV
- Stock Information
- Founded
- STRO 2003
- ACRV 2018
- Country
- STRO United States
- ACRV United States
- Employees
- STRO N/A
- ACRV N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- STRO Health Care
- ACRV Health Care
- Exchange
- STRO Nasdaq
- ACRV Nasdaq
- Market Cap
- STRO 172.8M
- ACRV 203.9M
- IPO Year
- STRO 2018
- ACRV 2022
- Fundamental
- Price
- STRO $2.08
- ACRV $7.18
- Analyst Decision
- STRO Strong Buy
- ACRV Strong Buy
- Analyst Count
- STRO 7
- ACRV 5
- Target Price
- STRO $12.14
- ACRV $22.40
- AVG Volume (30 Days)
- STRO 1.4M
- ACRV 51.7K
- Earning Date
- STRO 11-13-2024
- ACRV 11-13-2024
- Dividend Yield
- STRO N/A
- ACRV N/A
- EPS Growth
- STRO N/A
- ACRV N/A
- EPS
- STRO N/A
- ACRV N/A
- Revenue
- STRO $160,955,000.00
- ACRV N/A
- Revenue This Year
- STRO N/A
- ACRV N/A
- Revenue Next Year
- STRO N/A
- ACRV N/A
- P/E Ratio
- STRO N/A
- ACRV N/A
- Revenue Growth
- STRO 230.90
- ACRV N/A
- 52 Week Low
- STRO $2.04
- ACRV $3.19
- 52 Week High
- STRO $6.13
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- STRO 28.56
- ACRV 50.01
- Support Level
- STRO $2.66
- ACRV $6.80
- Resistance Level
- STRO $3.01
- ACRV $7.28
- Average True Range (ATR)
- STRO 0.19
- ACRV 0.45
- MACD
- STRO -0.04
- ACRV 0.06
- Stochastic Oscillator
- STRO 5.64
- ACRV 61.21
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.